Clovis Oncology Submits Supplemental New Drug Application For Rucaparib
October 09, 2017 at 22:14 PM EDT
CLVS announced today that the company has submitted a supplemental New Drug Application (sNDA) to the FDA for rucaparib as maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer .
